First-in-class therapies for severe neuromuscular disorders
NMD Pharma has raised €35M across 1 funding round from 5 investors, most recently a round in Feb 2022. Based in Aarhus, Denmark; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-02-20 | Other |
| €35M |
| INKEF Capital,Jeito Capital,Lundbeck Foundation,Novo Holdings,Roche Venture Fund |
| View deal → |
